BIOMEDICINE & PHARMACOTHERAPY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下： 2023年12月26号投稿 2024年1月31号 under review（送了好几位审稿人，最后2位同意审稿） 2024年2月9号 1审意见返回，其中一位要求补实验，另一位回答疑问（要求2月29号前返修） 那段时间过年回家加上忙毕业论文，时间来不及，写信申请延长至3月31号 2024年3月31号返修，其中一位审稿人疑似跑路，另一位审稿人建议接收 2024年4月4号编辑决定accept 2024年4月10号 online 总之，期刊编辑还是很人性化，处理邮件也很及时，一审审稿人问题很有启发，补充实验后确实能提升文章水平，其中一位审稿人跑路也没重新送审（很多期刊遇到这种情况都是再次送审，就挺耽误时间）。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：类风湿关节炎 经验分享：11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0 偏重的研究方向：类风湿学研究;inflammation;免疫学研究 经验分享：基础研究今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向：肿瘤;综述 经验分享：为啥找不到审稿人呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛？是不是还没有到proof。接收，proof,支付是三个邮件嘛？谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛，为什么支付完钱，然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=538529, encodeId=8c5853852909, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3月9号投稿，4月9号返回修改，没说明大修还是小修，但有5个审稿人，两个没什么意见，只是说明修改语言，另外三个分别提了5条左右的意见，给2个月时间修改，拖到6月2号修回去，隔了两天，又返回一个review的意见，补充了回答，然后6月8号再投，等了10天左右，19号接受，然后20号就给proof，今天见刊了！第一篇sci，很开心，跟大家分享下，希望大家都好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d72084065, createdName=1044216700_47666740, createdTime=Fri Jun 30 16:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省)]

2024-04-10 ms7000000856963905 来自北京

记录一下：
2023年12月26号投稿
2024年1月31号 under review（送了好几位审稿人，最后2位同意审稿）
2024年2月9号 1审意见返回，其中一位要求补实验，另一位回答疑问（要求2月29号前返修）
那段时间过年回家加上忙毕业论文，时间来不及，写信申请延长至3月31号
2024年3月31号返修，其中一位审稿人疑似跑路，另一位审稿人建议接收
2024年4月4号编辑决定accept
2024年4月10号 online
总之，期刊编辑还是很人性化，处理邮件也很及时，一审审稿人问题很有启发，补充实验后确实能提升文章水平，其中一位审稿人跑路也没重新送审（很多期刊遇到这种情况都是再次送审，就挺耽误时间）。

8 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下： 2023年12月26号投稿 2024年1月31号 under review（送了好几位审稿人，最后2位同意审稿） 2024年2月9号 1审意见返回，其中一位要求补实验，另一位回答疑问（要求2月29号前返修） 那段时间过年回家加上忙毕业论文，时间来不及，写信申请延长至3月31号 2024年3月31号返修，其中一位审稿人疑似跑路，另一位审稿人建议接收 2024年4月4号编辑决定accept 2024年4月10号 online 总之，期刊编辑还是很人性化，处理邮件也很及时，一审审稿人问题很有启发，补充实验后确实能提升文章水平，其中一位审稿人跑路也没重新送审（很多期刊遇到这种情况都是再次送审，就挺耽误时间）。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：类风湿关节炎 经验分享：11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0 偏重的研究方向：类风湿学研究;inflammation;免疫学研究 经验分享：基础研究今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向：肿瘤;综述 经验分享：为啥找不到审稿人呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛？是不是还没有到proof。接收，proof,支付是三个邮件嘛？谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛，为什么支付完钱，然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=538529, encodeId=8c5853852909, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3月9号投稿，4月9号返回修改，没说明大修还是小修，但有5个审稿人，两个没什么意见，只是说明修改语言，另外三个分别提了5条左右的意见，给2个月时间修改，拖到6月2号修回去，隔了两天，又返回一个review的意见，补充了回答，然后6月8号再投，等了10天左右，19号接受，然后20号就给proof，今天见刊了！第一篇sci，很开心，跟大家分享下，希望大家都好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d72084065, createdName=1044216700_47666740, createdTime=Fri Jun 30 16:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省)]

2024-04-06 14724b31m63暂无昵称来自吉林省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：类风湿关节炎
经验分享：11-17Submit New Manuscript
12-7Submissions Sent Back to Author 要求更改WB原始数据格式
12-13Submit New Manuscript
1-11With editor
1-14、1-16 1-17 1-29 Under review
2-13 Required Reviews completed
2-14Decision in progress
2-17Revise
3-7Revised Manuscript Submitted
3-7Under Review
3-15Revise
3-28 Revision submitted to journal
3-28Under Review
4-1Required Reviews Completed
4-4 Accepted

17 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下： 2023年12月26号投稿 2024年1月31号 under review（送了好几位审稿人，最后2位同意审稿） 2024年2月9号 1审意见返回，其中一位要求补实验，另一位回答疑问（要求2月29号前返修） 那段时间过年回家加上忙毕业论文，时间来不及，写信申请延长至3月31号 2024年3月31号返修，其中一位审稿人疑似跑路，另一位审稿人建议接收 2024年4月4号编辑决定accept 2024年4月10号 online 总之，期刊编辑还是很人性化，处理邮件也很及时，一审审稿人问题很有启发，补充实验后确实能提升文章水平，其中一位审稿人跑路也没重新送审（很多期刊遇到这种情况都是再次送审，就挺耽误时间）。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：类风湿关节炎 经验分享：11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0 偏重的研究方向：类风湿学研究;inflammation;免疫学研究 经验分享：基础研究今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向：肿瘤;综述 经验分享：为啥找不到审稿人呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛？是不是还没有到proof。接收，proof,支付是三个邮件嘛？谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛，为什么支付完钱，然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=538529, encodeId=8c5853852909, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3月9号投稿，4月9号返回修改，没说明大修还是小修，但有5个审稿人，两个没什么意见，只是说明修改语言，另外三个分别提了5条左右的意见，给2个月时间修改，拖到6月2号修回去，隔了两天，又返回一个review的意见，补充了回答，然后6月8号再投，等了10天左右，19号接受，然后20号就给proof，今天见刊了！第一篇sci，很开心，跟大家分享下，希望大家都好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d72084065, createdName=1044216700_47666740, createdTime=Fri Jun 30 16:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省)]

2024-03-29 Zhou zhongsheng 来自吉林

审稿速度:1.0
偏重的研究方向：类风湿学研究;inflammation;免疫学研究
经验分享：基础研究今天接收了

7 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下： 2023年12月26号投稿 2024年1月31号 under review（送了好几位审稿人，最后2位同意审稿） 2024年2月9号 1审意见返回，其中一位要求补实验，另一位回答疑问（要求2月29号前返修） 那段时间过年回家加上忙毕业论文，时间来不及，写信申请延长至3月31号 2024年3月31号返修，其中一位审稿人疑似跑路，另一位审稿人建议接收 2024年4月4号编辑决定accept 2024年4月10号 online 总之，期刊编辑还是很人性化，处理邮件也很及时，一审审稿人问题很有启发，补充实验后确实能提升文章水平，其中一位审稿人跑路也没重新送审（很多期刊遇到这种情况都是再次送审，就挺耽误时间）。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：类风湿关节炎 经验分享：11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0 偏重的研究方向：类风湿学研究;inflammation;免疫学研究 经验分享：基础研究今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向：肿瘤;综述 经验分享：为啥找不到审稿人呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛？是不是还没有到proof。接收，proof,支付是三个邮件嘛？谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛，为什么支付完钱，然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=538529, encodeId=8c5853852909, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3月9号投稿，4月9号返回修改，没说明大修还是小修，但有5个审稿人，两个没什么意见，只是说明修改语言，另外三个分别提了5条左右的意见，给2个月时间修改，拖到6月2号修回去，隔了两天，又返回一个review的意见，补充了回答，然后6月8号再投，等了10天左右，19号接受，然后20号就给proof，今天见刊了！第一篇sci，很开心，跟大家分享下，希望大家都好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d72084065, createdName=1044216700_47666740, createdTime=Fri Jun 30 16:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省)]

2024-03-13 ms2000001254072347 来自四川省

偏重的研究方向：肿瘤;综述
经验分享：为啥找不到审稿人呢

13 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下： 2023年12月26号投稿 2024年1月31号 under review（送了好几位审稿人，最后2位同意审稿） 2024年2月9号 1审意见返回，其中一位要求补实验，另一位回答疑问（要求2月29号前返修） 那段时间过年回家加上忙毕业论文，时间来不及，写信申请延长至3月31号 2024年3月31号返修，其中一位审稿人疑似跑路，另一位审稿人建议接收 2024年4月4号编辑决定accept 2024年4月10号 online 总之，期刊编辑还是很人性化，处理邮件也很及时，一审审稿人问题很有启发，补充实验后确实能提升文章水平，其中一位审稿人跑路也没重新送审（很多期刊遇到这种情况都是再次送审，就挺耽误时间）。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：类风湿关节炎 经验分享：11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0 偏重的研究方向：类风湿学研究;inflammation;免疫学研究 经验分享：基础研究今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向：肿瘤;综述 经验分享：为啥找不到审稿人呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛？是不是还没有到proof。接收，proof,支付是三个邮件嘛？谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛，为什么支付完钱，然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=538529, encodeId=8c5853852909, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3月9号投稿，4月9号返回修改，没说明大修还是小修，但有5个审稿人，两个没什么意见，只是说明修改语言，另外三个分别提了5条左右的意见，给2个月时间修改，拖到6月2号修回去，隔了两天，又返回一个review的意见，补充了回答，然后6月8号再投，等了10天左右，19号接受，然后20号就给proof，今天见刊了！第一篇sci，很开心，跟大家分享下，希望大家都好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d72084065, createdName=1044216700_47666740, createdTime=Fri Jun 30 16:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省)]

2024-01-31 ms8000001441772842 来自北京

多久有人愿意审稿呀。

23 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下： 2023年12月26号投稿 2024年1月31号 under review（送了好几位审稿人，最后2位同意审稿） 2024年2月9号 1审意见返回，其中一位要求补实验，另一位回答疑问（要求2月29号前返修） 那段时间过年回家加上忙毕业论文，时间来不及，写信申请延长至3月31号 2024年3月31号返修，其中一位审稿人疑似跑路，另一位审稿人建议接收 2024年4月4号编辑决定accept 2024年4月10号 online 总之，期刊编辑还是很人性化，处理邮件也很及时，一审审稿人问题很有启发，补充实验后确实能提升文章水平，其中一位审稿人跑路也没重新送审（很多期刊遇到这种情况都是再次送审，就挺耽误时间）。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：类风湿关节炎 经验分享：11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0 偏重的研究方向：类风湿学研究;inflammation;免疫学研究 经验分享：基础研究今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向：肿瘤;综述 经验分享：为啥找不到审稿人呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛？是不是还没有到proof。接收，proof,支付是三个邮件嘛？谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛，为什么支付完钱，然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=538529, encodeId=8c5853852909, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3月9号投稿，4月9号返回修改，没说明大修还是小修，但有5个审稿人，两个没什么意见，只是说明修改语言，另外三个分别提了5条左右的意见，给2个月时间修改，拖到6月2号修回去，隔了两天，又返回一个review的意见，补充了回答，然后6月8号再投，等了10天左右，19号接受，然后20号就给proof，今天见刊了！第一篇sci，很开心，跟大家分享下，希望大家都好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d72084065, createdName=1044216700_47666740, createdTime=Fri Jun 30 16:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省)]

2024-03-08 chy 来自辽宁省

记录一下，2.16投稿的，1300+，今天还是Submitted to journal

91 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下： 2023年12月26号投稿 2024年1月31号 under review（送了好几位审稿人，最后2位同意审稿） 2024年2月9号 1审意见返回，其中一位要求补实验，另一位回答疑问（要求2月29号前返修） 那段时间过年回家加上忙毕业论文，时间来不及，写信申请延长至3月31号 2024年3月31号返修，其中一位审稿人疑似跑路，另一位审稿人建议接收 2024年4月4号编辑决定accept 2024年4月10号 online 总之，期刊编辑还是很人性化，处理邮件也很及时，一审审稿人问题很有启发，补充实验后确实能提升文章水平，其中一位审稿人跑路也没重新送审（很多期刊遇到这种情况都是再次送审，就挺耽误时间）。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：类风湿关节炎 经验分享：11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0 偏重的研究方向：类风湿学研究;inflammation;免疫学研究 经验分享：基础研究今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向：肿瘤;综述 经验分享：为啥找不到审稿人呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛？是不是还没有到proof。接收，proof,支付是三个邮件嘛？谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛，为什么支付完钱，然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=538529, encodeId=8c5853852909, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3月9号投稿，4月9号返回修改，没说明大修还是小修，但有5个审稿人，两个没什么意见，只是说明修改语言，另外三个分别提了5条左右的意见，给2个月时间修改，拖到6月2号修回去，隔了两天，又返回一个review的意见，补充了回答，然后6月8号再投，等了10天左右，19号接受，然后20号就给proof，今天见刊了！第一篇sci，很开心，跟大家分享下，希望大家都好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d72084065, createdName=1044216700_47666740, createdTime=Fri Jun 30 16:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省)]

2024-03-28 ms8000001441772842 来自北京

精彩评论，需要您登录查看

7 4

[GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下： 2023年12月26号投稿 2024年1月31号 under review（送了好几位审稿人，最后2位同意审稿） 2024年2月9号 1审意见返回，其中一位要求补实验，另一位回答疑问（要求2月29号前返修） 那段时间过年回家加上忙毕业论文，时间来不及，写信申请延长至3月31号 2024年3月31号返修，其中一位审稿人疑似跑路，另一位审稿人建议接收 2024年4月4号编辑决定accept 2024年4月10号 online 总之，期刊编辑还是很人性化，处理邮件也很及时，一审审稿人问题很有启发，补充实验后确实能提升文章水平，其中一位审稿人跑路也没重新送审（很多期刊遇到这种情况都是再次送审，就挺耽误时间）。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：类风湿关节炎 经验分享：11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0 偏重的研究方向：类风湿学研究;inflammation;免疫学研究 经验分享：基础研究今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向：肿瘤;综述 经验分享：为啥找不到审稿人呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛？是不是还没有到proof。接收，proof,支付是三个邮件嘛？谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛，为什么支付完钱，然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=538529, encodeId=8c5853852909, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3月9号投稿，4月9号返回修改，没说明大修还是小修，但有5个审稿人，两个没什么意见，只是说明修改语言，另外三个分别提了5条左右的意见，给2个月时间修改，拖到6月2号修回去，隔了两天，又返回一个review的意见，补充了回答，然后6月8号再投，等了10天左右，19号接受，然后20号就给proof，今天见刊了！第一篇sci，很开心，跟大家分享下，希望大家都好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d72084065, createdName=1044216700_47666740, createdTime=Fri Jun 30 16:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省)]

2024-03-31 ms8000001441772842 来自北京

有所有作者签字**版权的环节嘛，为什么支付完钱，然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!

7 0

[GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下： 2023年12月26号投稿 2024年1月31号 under review（送了好几位审稿人，最后2位同意审稿） 2024年2月9号 1审意见返回，其中一位要求补实验，另一位回答疑问（要求2月29号前返修） 那段时间过年回家加上忙毕业论文，时间来不及，写信申请延长至3月31号 2024年3月31号返修，其中一位审稿人疑似跑路，另一位审稿人建议接收 2024年4月4号编辑决定accept 2024年4月10号 online 总之，期刊编辑还是很人性化，处理邮件也很及时，一审审稿人问题很有启发，补充实验后确实能提升文章水平，其中一位审稿人跑路也没重新送审（很多期刊遇到这种情况都是再次送审，就挺耽误时间）。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：类风湿关节炎 经验分享：11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0 偏重的研究方向：类风湿学研究;inflammation;免疫学研究 经验分享：基础研究今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向：肿瘤;综述 经验分享：为啥找不到审稿人呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛？是不是还没有到proof。接收，proof,支付是三个邮件嘛？谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛，为什么支付完钱，然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=538529, encodeId=8c5853852909, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3月9号投稿，4月9号返回修改，没说明大修还是小修，但有5个审稿人，两个没什么意见，只是说明修改语言，另外三个分别提了5条左右的意见，给2个月时间修改，拖到6月2号修回去，隔了两天，又返回一个review的意见，补充了回答，然后6月8号再投，等了10天左右，19号接受，然后20号就给proof，今天见刊了！第一篇sci，很开心，跟大家分享下，希望大家都好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d72084065, createdName=1044216700_47666740, createdTime=Fri Jun 30 16:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省)]

2017-06-30 1044216700_47666740

审稿速度:1.0 | 投稿命中率:25.0
经验分享：3月9号投稿，4月9号返回修改，没说明大修还是小修，但有5个审稿人，两个没什么意见，只是说明修改语言，另外三个分别提了5条左右的意见，给2个月时间修改，拖到6月2号修回去，隔了两天，又返回一个review的意见，补充了回答，然后6月8号再投，等了10天左右，19号接受，然后20号就给proof，今天见刊了！第一篇sci，很开心，跟大家分享下，希望大家都好运

224 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下： 2023年12月26号投稿 2024年1月31号 under review（送了好几位审稿人，最后2位同意审稿） 2024年2月9号 1审意见返回，其中一位要求补实验，另一位回答疑问（要求2月29号前返修） 那段时间过年回家加上忙毕业论文，时间来不及，写信申请延长至3月31号 2024年3月31号返修，其中一位审稿人疑似跑路，另一位审稿人建议接收 2024年4月4号编辑决定accept 2024年4月10号 online 总之，期刊编辑还是很人性化，处理邮件也很及时，一审审稿人问题很有启发，补充实验后确实能提升文章水平，其中一位审稿人跑路也没重新送审（很多期刊遇到这种情况都是再次送审，就挺耽误时间）。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：类风湿关节炎 经验分享：11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0 偏重的研究方向：类风湿学研究;inflammation;免疫学研究 经验分享：基础研究今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向：肿瘤;综述 经验分享：为啥找不到审稿人呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛？是不是还没有到proof。接收，proof,支付是三个邮件嘛？谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛，为什么支付完钱，然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=538529, encodeId=8c5853852909, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3月9号投稿，4月9号返回修改，没说明大修还是小修，但有5个审稿人，两个没什么意见，只是说明修改语言，另外三个分别提了5条左右的意见，给2个月时间修改，拖到6月2号修回去，隔了两天，又返回一个review的意见，补充了回答，然后6月8号再投，等了10天左右，19号接受，然后20号就给proof，今天见刊了！第一篇sci，很开心，跟大家分享下，希望大家都好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d72084065, createdName=1044216700_47666740, createdTime=Fri Jun 30 16:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省)]

2023-07-31 ms6000001702952186 来自湖南省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：分子生物学;肿瘤;综述
经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运

40 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务